{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:44:42Z","timestamp":1790379882871,"version":"4.1.0"},"reference-count":43,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"publisher","award":["503\/1-152-01\/503-11-002"],"award-info":[{"award-number":["503\/1-152-01\/503-11-002"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In recent years, monoclonal antibodies targeting key cytokines underlying the occurrence of psoriatic skin lesions and joint involvement, i.e., Tumor Necrosis Factor-alpha (TNF-\u03b1), Interleukin 17 (IL-17), Interleukin 12 (IL-12), and Interleukin 23 (IL-23), have become more commonly used in the therapy of psoriasis. Due to the high effectiveness, a favorable safety profile, and growing availability of biological treatment methods, the number of patients receiving chronic monoclonal antibody therapy is increasing each year. However, the factors affecting the effectiveness of biological drugs are not fully recognized. The study aimed at analyzing the clinical profile of patients and non-specific inflammatory markers in terms of the response to the psoriasis treatment with IL-17, IL-23, IL-12\/23, and TNF-\u03b1 inhibitors. The analysis involved 185 patients receiving biological therapy in the Department of Dermatology and Venereology at the Medical University of Lodz, which resulted in a total of 222 treatment cycles (TC). The super-response was defined as 100% reduction in the Psoriasis Area and Severity Index (PASI 100), at week 16 (\u00b14 weeks) of therapy. Our study indicates that the chance of achieving a super-response was higher among younger patients with no psoriatic lesions on palms and soles, not suffering from non-alcoholic fatty liver disease, previously treated with methotrexate, and characterized by a higher level of derived Neutrophil-to-Lymphocyte Ratio (dNLR) at the beginning of treatment.<\/jats:p>","DOI":"10.3390\/ijms262110770","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:09:47Z","timestamp":1762358987000},"page":"10770","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Blood-Count-Derived Inflammatory Biomarkers and Characterization of Super-Responder Profile in Psoriatic Patients Receiving Biological Treatment: A Single-Center Study"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6705-5837","authenticated-orcid":false,"given":"Agnieszka","family":"Ho\u0142drowicz","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Lodz, 90-647 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"Zajdel","sequence":"additional","affiliation":[{"name":"Department of Economic and Medical Informatics, University of Lodz, 90-214 Lodz, Poland"},{"name":"Department of AI in Healthcare, Medical University of Lodz, 90-645 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4548-3080","authenticated-orcid":false,"given":"Agnieszka","family":"\u017bebrowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Lodz, 90-647 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Secchiero, P., Rimondi, E., Marcuzzi, A., Longo, G., Papi, C., Manfredini, M., Fields, M., Caruso, L., Di Caprio, R., and Balato, A. (2024). Metabolic Syndrome and Psoriasis: Pivotal Roles of Chronic Inflammation and Gut Microbiota. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158098"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.reuma.2023.05.004","article-title":"Osteoporosis in psoriatic arthritis: Risk factors, insufficiency fractures and its association with the disease activity","volume":"20","author":"Jovani","year":"2024","journal-title":"Reumatol. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/mr\/roae028","article-title":"Osteoporosis and osteopenia in patients with psoriatic arthritis: A single-centre retrospective study","volume":"34","author":"Takami","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00403-025-03805-y","article-title":"The impact of body mass index on the relationship between psoriasis and Osteopenia: A mediating analysis based on NHANES (2003\u20132006)","volume":"317","author":"Xu","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12016-025-09089-4","article-title":"Systemic Psoriasis: From Molecular Mechanisms to Global Management Strategies","volume":"68","author":"Prema","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/exd.14731","article-title":"\u201cSuperresponders\u201d at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104\u2009weeks","volume":"37","author":"Rompoti","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1080\/09546634.2021.1898528","article-title":"Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis","volume":"33","author":"Feldman","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jdv.18126","article-title":"Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: A nationwide study","volume":"36","author":"Loft","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14712598.2021.1862082","article-title":"HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis","volume":"21","author":"Morelli","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1111\/jdv.15659","article-title":"High-resolution HLA typing identifies a new \u2018super responder\u2019 subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02\/HLA-C*04, in response to ustekinumab","volume":"33","author":"Talamonti","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/PTT.S514249","article-title":"Real-World Experience of Bimekizumab in a Cohort of109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events","volume":"15","author":"Fratton","year":"2025","journal-title":"Psoriasis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/bjd\/ljad280","article-title":"How to define a \u2018super-responder\u2019 to biologics in psoriasis studies","volume":"189","author":"Thomas","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Reich","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/jdv.18474","article-title":"Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: Age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator\u2019s Global Assessment scores predict complete skin clearance","volume":"36","author":"Reich","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s13555-025-01394-2","article-title":"Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study","volume":"15","author":"Mortato","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2025.02.063","article-title":"Characterization and treatment outcomes of biologic therapy in super-responders and biologic-refractory psoriasis patients: A single-center retrospective study in China","volume":"93","author":"Liu","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/1346-8138.17866","article-title":"Long-Term Impact of Guselkumab on Skin, Sexuality, and Perceived Stigmatization in Patients With Psoriasis in Routine Clinical Practice: Week 76 Effectiveness and Safety Results From the Prospective German Multicenter G-EPOSS Study","volume":"52","author":"Gerdes","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1111\/jdv.19464","article-title":"A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)","volume":"38","author":"Gargiulo","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40261-025-01440-z","article-title":"Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis)","volume":"45","author":"Esposito","year":"2025","journal-title":"Clin. Drug Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2331782","DOI":"10.1080\/09546634.2024.2331782","article-title":"Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: A real-life cohort study on the effectiveness and drug survival over one-year","volume":"35","author":"Liu","year":"2024","journal-title":"J. Dermtol. Treat."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Marcelli, L., Belcastro, A., Talamonti, M., Paganini, C., Fico, A., Savastano, L., Di Raimondo, C., Vellucci, L., Bianchi, L., and Galluzzo, M. (2024). Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175175"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ruiz-Villaverde, R., Vasquez-Chinchay, F., Rodriguez-Fernandez-Freire, L.C., Armario-Hita, J., P\u00e9rez-Gil, A., and Gal\u00e1n-Guti\u00e9rrez, M. (2022). Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives. Life, 12.","DOI":"10.3390\/life12091412"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/bjd\/ljad446","article-title":"BADBIR Study Group. Characteristics of \u2018super responders\u2019 and \u2018super nonresponders\u2019 to first biologic monotherapy for psoriasis: A nested case-control study","volume":"190","author":"Mason","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_25","first-page":"e1321","article-title":"Super-responders in psoriasis under interleukin 23 inhibitor treatments, experience in two centres","volume":"37","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ziolkowska-Banasik, D., Pastuszczak, M., Zawadzinska-Halat, K., Hadas, E., and Bozek, A. (2025). Serum IL-18\/IL-13 Ratio Predicts Super Response to Secukinumab in Patients with Psoriasis. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202506.1120.v1"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Morariu, S.H., Cotoi, O.S., Tiuc\u0103, O.M., Baican, A., Gheuc\u0103-Solov\u0103stru, L., Decean, H., Brihan, I., Silaghi, K., Biro, V., and \u0218erban-Pescar, D. (2024). Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13143992"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jaad.2025.02.015","article-title":"Patients with PSOriasis and Suppurative Hidradenitis (PSO-SH) share genetic risk factors and are at risk of increased morbidity","volume":"92","author":"Wiala","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Untaaveesup, S., Kantagowit, P., Ungprasert, P., Kitlertbanchong, N., Vajiraviroj, T., Sutithavinkul, T., Techataweewan, G., Eiumtrakul, W., Threethrong, R., and Chaemsupaphan, T. (2025). The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. J. Clin. Med., 14.","DOI":"10.37766\/inplasy2025.1.0068"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"9964486","DOI":"10.1155\/cjgh\/9964486","article-title":"Risk Factors Related to the Development of Nonalcoholic Fatty Liver: A Systematic Review","volume":"2025","author":"Valencia","year":"2025","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Costache, D.O., Blejan, H., Cojocaru, D.L., Ioni\u021b\u0103, G.A., Poenaru, M., Constantin, M.M., Costache, A.C., C\u0103runtu, C., Balaban, D.V., and Costache, R.S. (2024). Intersecting Pathways: Nonalcoholic Fatty Liver Disease and Psoriasis Duet-A Comprehensive Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052660"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-024-06015-8","article-title":"Multi-ancestry genome-wide meta-analysis with 472,819 individuals identifies 32 novel risk loci for psoriasis","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjd.15387","article-title":"Role of the HLA-C*06 allele in clinical response to ustekinumab: Evidence from real life in a large cohort of European patients","volume":"177","author":"Talamonti","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/tpj.2016.64","article-title":"New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Cabaleiro","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ad.2025.03.030","article-title":"Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice","volume":"116","author":"Armesto","year":"2025","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Andersen, C.S.B., Kvist-Hansen, A., Siewertsen, M., Enevold, C., Hansen, P.R., Kaur-Knudsen, D., Zachariae, C., Nielsen, C.H., Loft, N., and Skov, L. (2023). Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076111"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Oliveri, C., Xourafa, A., Agostino, R.M., Corigliano, V., Botindari, A., Gaudio, A., Morabito, N., Allegra, A., and Catalano, A. (2025). Exploring the Association Between Platelet Count, the Systemic Immune Inflammation Index, and Fracture Risk in Postmenopausal Women with Osteoporosis: A Cross-Sectional Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155453"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Firinci, B., Aydin, C., Yunluel, D., Ibrahim, A., Yigiter, M., and Ahiskalioglu, A. (2025). The Role of Systemic Immune-Inflammation Index (SII) in Diagnosing Pediatric Acute Appendicitis. Diagnostics, 15.","DOI":"10.3390\/diagnostics15151942"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Liu, J., He, T., and Liu, C. (2025). The predictive value of NLR, SII, and complement 3 in treatment response for systemic lupus erythematosus with immune thrombocytopenia. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1606510"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e2024065","DOI":"10.5826\/dpc.1401a65","article-title":"Effect of Treatment with Biologic Agents on the Novel Inflammatory Biomarkers Systemic Immune Inflammation Index and Systemic Inflammation Response Index for Psoriasis","volume":"14","author":"Tamer","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s11845-025-03969-6","article-title":"The effect of IL-17 and IL-23 \u0131nhibitors on hematological\u0131nflammatory parameters in patients with psoriasis vulgaris","volume":"194","year":"2025","journal-title":"Ir. J. Med. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000545148","article-title":"Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil\/Lymphocyte Ratio, Platelet\/Lymphocyte Ratio, and Monocyte\/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials","volume":"241","author":"Kearney","year":"2025","journal-title":"Dermatology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Tiuc\u0103, O.M., Morariu, S.H., Mariean, C.R., Tiuc\u0103, R.A., Nicolescu, A.C., and Cotoi, O.S. (2024). Impact of Blood-Count-Derived Inflammatory Markers in Psoriatic Disease Progression. Life, 14.","DOI":"10.3390\/life14010114"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10770\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:19:55Z","timestamp":1762492795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":43,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ijms262110770"],"URL":"https:\/\/doi.org\/10.3390\/ijms262110770","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}